Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Sofpironium Bromide Gel in Axillary Hyperhidrosis
NCT03627468Phase 3Completed
- Sponsor
- Botanix Pharmaceuticals
- Start
- Sep 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sofpironium in primary axillary hyperhidrosis (PAH), sponsored by Botanix Pharmaceuticals. Started Sep 2018; status: completed.
02
Drugs
sofpironium
03
Conditions
primary axillary hyperhidrosis (PAH)
Beyond the preview
Go deeper on NCT03627468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627468.